Outcome measures in rheumatoid arthritis randomised trials over the last 50 years

Trials

Paula R Williamson⁴  Mike Clarke²  Peter Tugwell¹  Maarten Boers³  Jamie J Kirkham⁴ 

[1] Department of Medicine, University of Ottawa, K1N 6N5, Ottawa, Ontario, Canada;Centre for Public Health, Queen’s University Belfast, BT12 6BA, Belfast, United Kingdom;Department of Epidemiology and Biostatistics, VU Medical Center, Amsterdam, the Netherlands;Department of Biostatistics, University of Liverpool, L69 3GA, Liverpool, United Kingdom

关键词: Rheumatoid arthritis;    Outcome reporting bias;    OMERACT;    Core outcome set;    COMET;   

Others  :  1092940
DOI  :  10.1186/1745-6215-14-324

 received in 2013-03-28, accepted in 2013-09-24,  发布年份 2013

【 摘 要 】

Background

The development and application of standardised sets of outcomes to be measured and reported in clinical trials have the potential to increase the efficiency and value of research. One of the most notable of the current outcome sets began nearly 20 years ago: the World Health Organization and International League of Associations for Rheumatology core set of outcomes for rheumatoid arthritis clinical trials, originating from the OMERACT (Outcome Measures in Rheumatology) Initiative. This study assesses the use of this core outcome set by randomised trials in rheumatology.

Methods

An observational review was carried out of 350 randomised trials for the treatment of rheumatoid arthritis identified through The Cochrane Library (up to and including September 2012 issue). Reports of these trials were evaluated to determine whether or not there were trends in the proportion of trials reporting on the full set of core outcomes over time. Researchers who conducted trials after the publication of the core set were contacted to assess their awareness of it and to collect reasons for non-inclusion of the full core set of outcomes in the study.

Results

Since the introduction of the core set of outcomes for rheumatoid arthritis, the consistency of measurement of the core set of outcomes has improved, although variation in the choice of measurement instrument remains. The majority of trialists who responded said that they would consider using the core outcome set in the design of a new trial.

Conclusions

This observational review suggests that a higher percentage of trialists conducting trials in rheumatoid arthritis are now measuring the rheumatoid arthritis core outcome set. Core outcome sets have the potential to improve the evidence base for health care, but consideration must be given to the methods for disseminating their availability amongst the relevant communities.

【 授权许可】

   
2013 Kirkham et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, Decullier E, Easterbrook PJ, von Elm E, Gamble C, Ghersi D, Ioannidis JPA, Simes J, Williamson PR: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 2008, 3(8):e3081.
• [2]Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, Williamson PR: The impact of outcome reporting bias on systematic reviews. BMJ 2010, 340:c365.
• [3]Clarke M: Standardising outcomes for clinical trials and systematic reviews. Trials 2007, 8:39. BioMed Central Full Text
• [4]Williamson PR, Altman D, Blazeby J, Clarke M, Gargon E: Driving up the quality and relevance of research through the use of agreed core outcomes. J Health Serv Res Policy 2012, 17(1):1-2.
• [5]Felson DT, Anderson JJ, Meenan RF: Time for changes in the design, analysis, and reprint of rheumatoid arthritis clinical trials. Arthritis Rheum 1990, 33:140-149.
• [6]Tugwell P, Boers M, Brooks P, Simon L, Strande V, Idzerda L: OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007, 8:38. BioMed Central Full Text
• [7]Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, Smolen JS, Khaltaev N, Muirden KD: World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994, 21(suppl 41):86-89.
• [8]http://ctrc.liv.ac.uk/orbit/ (accessed 6 October 2013)
• [9]Van der Heijde DM, Van ’t Hof MA, Van Riel PL, van de Putte LB: Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 1993, 20:579-581.
• [10]Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, James Williams H, Wolfe F: The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 1993, 36(6):729-740.
• [11]US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). 1999. [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071579.pdf webcite]
• [12]The European Agency for the Evaluation of Medicinal Products, Unit for the Evaluation of Medicinal Products for Human Use: Guideline on Clinical Investigation of Medicinal Products other than NSAIDs for Treatment of Rheumatoid Arthritis. 2003. [http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003439.pdf webcite]
• [13]Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, Hazes M, Richard P, Saag K, Suarez-Almazor M, Wells G, Hewlett S: Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007, 34(5):1174-1177.
• [14]Schmitt J, Langan S, Stamm T, Williams HC: Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol 2011, 131(3):623-630.
• [15]Sinha IP, Gallagher R, Williamson PR, Smyth RL: Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. Trials 2012, 13:103. BioMed Central Full Text
• [16]COMET initiative: Core Outcome Measures in Effectiveness Trials. [http://www.comet-initiative.org/ webcite]